Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: ZFP36L2

Gene summary for ZFP36L2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

ZFP36L2

Gene ID

678

Gene nameZFP36 ring finger protein like 2
Gene AliasBRF2
Cytomap2p21
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

P47974


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
678ZFP36L2GSM4909281HumanBreastIDC4.01e-02-2.68e-010.21
678ZFP36L2GSM4909282HumanBreastIDC2.61e-165.70e-01-0.0288
678ZFP36L2GSM4909285HumanBreastIDC6.31e-10-3.03e-010.21
678ZFP36L2GSM4909286HumanBreastIDC3.52e-14-5.12e-010.1081
678ZFP36L2GSM4909290HumanBreastIDC1.50e-04-5.10e-010.2096
678ZFP36L2GSM4909291HumanBreastIDC4.35e-03-4.76e-010.1753
678ZFP36L2GSM4909293HumanBreastIDC2.71e-05-4.26e-010.1581
678ZFP36L2GSM4909294HumanBreastIDC1.33e-03-3.12e-010.2022
678ZFP36L2GSM4909296HumanBreastIDC2.43e-17-5.86e-010.1524
678ZFP36L2GSM4909297HumanBreastIDC1.81e-11-4.31e-010.1517
678ZFP36L2GSM4909301HumanBreastIDC2.45e-11-5.42e-010.1577
678ZFP36L2GSM4909302HumanBreastIDC1.39e-02-3.62e-010.1545
678ZFP36L2GSM4909304HumanBreastIDC9.90e-11-5.62e-010.1636
678ZFP36L2GSM4909305HumanBreastIDC1.42e-063.73e-010.0436
678ZFP36L2GSM4909307HumanBreastIDC4.40e-14-6.04e-010.1569
678ZFP36L2GSM4909308HumanBreastIDC6.80e-13-6.41e-010.158
678ZFP36L2GSM4909311HumanBreastIDC9.12e-35-7.03e-010.1534
678ZFP36L2GSM4909312HumanBreastIDC2.70e-07-4.58e-010.1552
678ZFP36L2GSM4909315HumanBreastIDC1.62e-19-6.40e-010.21
678ZFP36L2GSM4909316HumanBreastIDC6.23e-03-5.78e-010.21
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
BreastThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.IDC: Invasive ductal carcinoma
DCIS: Ductal carcinoma in situ
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
CervixThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CC: Cervix cancer
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
GCThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CAG: Chronic atrophic gastritis
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
CSG: Chronic superficial gastritis
GC: Gastric cancer
SIM: Severe intestinal metaplasia
WIM: Wild intestinal metaplasia
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:004427014ProstateBPHcellular nitrogen compound catabolic process112/3107451/187234.04e-066.12e-05112
GO:00171484ProstateBPHnegative regulation of translation68/3107245/187237.01e-061.01e-0468
GO:00987276ProstateBPHmaintenance of cell number43/3107134/187237.29e-061.04e-0443
GO:00198275ProstateBPHstem cell population maintenance42/3107131/187239.49e-061.33e-0442
GO:001943910ProstateBPHaromatic compound catabolic process113/3107467/187231.30e-051.72e-04113
GO:190136110ProstateBPHorganic cyclic compound catabolic process118/3107495/187231.75e-052.17e-04118
GO:00713847ProstateBPHcellular response to corticosteroid stimulus24/310761/187231.86e-052.29e-0424
GO:003461216ProstateBPHresponse to tumor necrosis factor68/3107253/187232.22e-052.67e-0468
GO:19019904ProstateBPHregulation of mitotic cell cycle phase transition77/3107299/187233.36e-053.77e-0477
GO:00610148ProstateBPHpositive regulation of mRNA catabolic process30/310787/187233.72e-054.04e-0430
GO:00611578ProstateBPHmRNA destabilization29/310784/187234.86e-055.07e-0429
GO:20007373ProstateBPHnegative regulation of stem cell differentiation12/310723/187239.46e-058.88e-0412
GO:19021058ProstateBPHregulation of leukocyte differentiation71/3107279/187239.94e-059.21e-0471
GO:00507798ProstateBPHRNA destabilization29/310788/187231.26e-041.14e-0329
GO:007135616ProstateBPHcellular response to tumor necrosis factor60/3107229/187231.42e-041.26e-0360
GO:00488636ProstateBPHstem cell differentiation55/3107206/187231.56e-041.36e-0355
GO:19001537ProstateBPHpositive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay9/310715/187231.81e-041.53e-039
GO:19001518ProstateBPHregulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay10/310718/187231.87e-041.55e-0310
GO:00457863ProstateBPHnegative regulation of cell cycle91/3107385/187232.10e-041.71e-0391
GO:004211010ProstateBPHT cell activation111/3107487/187232.11e-041.72e-03111
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa042189BreastPrecancerCellular senescence29/684156/84651.66e-051.69e-041.30e-0429
hsa0421814BreastPrecancerCellular senescence29/684156/84651.66e-051.69e-041.30e-0429
hsa0421824BreastIDCCellular senescence35/867156/84655.49e-067.43e-055.56e-0535
hsa0421834BreastIDCCellular senescence35/867156/84655.49e-067.43e-055.56e-0535
hsa0421844BreastDCISCellular senescence34/846156/84658.53e-061.06e-047.80e-0534
hsa0421854BreastDCISCellular senescence34/846156/84658.53e-061.06e-047.80e-0534
hsa0421810CervixCCCellular senescence49/1267156/84651.30e-071.63e-069.61e-0749
hsa0421815CervixCCCellular senescence49/1267156/84651.30e-071.63e-069.61e-0749
hsa04218ColorectumADCellular senescence53/2092156/84655.55e-032.48e-021.58e-0253
hsa042181ColorectumADCellular senescence53/2092156/84655.55e-032.48e-021.58e-0253
hsa042182ColorectumMSSCellular senescence52/1875156/84657.87e-045.07e-033.11e-0352
hsa042183ColorectumMSSCellular senescence52/1875156/84657.87e-045.07e-033.11e-0352
hsa042184ColorectumFAPCellular senescence42/1404156/84656.79e-044.63e-032.82e-0342
hsa042185ColorectumFAPCellular senescence42/1404156/84656.79e-044.63e-032.82e-0342
hsa0421816EndometriumAEHCellular senescence37/1197156/84658.49e-045.52e-034.04e-0337
hsa0421817EndometriumAEHCellular senescence37/1197156/84658.49e-045.52e-034.04e-0337
hsa0421825EndometriumEECCellular senescence40/1237156/84651.89e-041.68e-031.25e-0340
hsa0421835EndometriumEECCellular senescence40/1237156/84651.89e-041.68e-031.25e-0340
hsa0421829EsophagusESCCCellular senescence119/4205156/84655.89e-129.40e-114.81e-11119
hsa0421838EsophagusESCCCellular senescence119/4205156/84655.89e-129.40e-114.81e-11119
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
ZFP36L2SNVMissense_Mutationc.376G>Cp.Glu126Glnp.E126QP47974protein_codingdeleterious(0)possibly_damaging(0.86)TCGA-BH-A0W7-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapytaxotereCR
ZFP36L2SNVMissense_Mutationc.5N>Gp.Ser2Trpp.S2WP47974protein_codingdeleterious(0)probably_damaging(1)TCGA-E2-A10C-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycytoxanSD
ZFP36L2SNVMissense_Mutationc.469N>Ap.Glu157Lysp.E157KP47974protein_codingdeleterious(0)probably_damaging(0.998)TCGA-EW-A1PA-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycyclophosphamideSD
ZFP36L2SNVMissense_Mutationnovelc.73N>Tp.Leu25Phep.L25FP47974protein_codingtolerated(0.61)possibly_damaging(0.875)TCGA-JL-A3YX-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
ZFP36L2insertionFrame_Shift_Insnovelc.111_112insGp.Thr38AspfsTer46p.T38Dfs*46P47974protein_codingTCGA-AR-A1AQ-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinSD
ZFP36L2SNVMissense_Mutationc.57G>Cp.Glu19Aspp.E19DP47974protein_codingtolerated(0.21)benign(0.027)TCGA-C5-A3HE-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownPD
ZFP36L2SNVMissense_Mutationc.137N>Tp.Ser46Leup.S46LP47974protein_codingdeleterious(0)benign(0.203)TCGA-C5-A7CO-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycisplatinSD
ZFP36L2SNVMissense_Mutationnovelc.635N>Ap.Cys212Tyrp.C212YP47974protein_codingdeleterious(0)probably_damaging(0.947)TCGA-C5-A8XH-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
ZFP36L2SNVMissense_Mutationrs761179005c.401N>Ap.Leu134Hisp.L134HP47974protein_codingtolerated(0.1)probably_damaging(0.937)TCGA-DS-A7WH-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
ZFP36L2SNVMissense_Mutationnovelc.423G>Cp.Gln141Hisp.Q141HP47974protein_codingtolerated(0.11)possibly_damaging(0.694)TCGA-EK-A2PG-01Cervixcervical & endocervical cancerFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 6 7 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
678ZFP36L2TRANSCRIPTION FACTORBUTYRATE10367403
Page: 1